Get the latest news, insights, and market updates on NPCE (NeuroPace, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
NeuroPace Inc.: Q2 Earnings Snapshot
MOUNTAIN VIEW, Calif. AP) — NeuroPace Inc. NPCE) on Tuesday reported a loss of $8.7 million in its second quarter. Aug 12, 2025 - $NPCE
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device comp Aug 12, 2025 - $NPCE
Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates
Orthofix (OFIX) delivered earnings and revenue surprises of +225.00% and +3.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Aug 5, 2025 - $NPCE
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule. “We appreciate CMS’ openness to public comment on the prop Aug 1, 2025 - $NPCE
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2025 after market close on Tuesday, August 12, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may Jul 29, 2025 - $NPCE
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +76.92% and +7.52%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock? Jul 15, 2025 - $NPCE
NeuroPace Announces Strategic CFO Transition
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Reb Jun 24, 2025 - $NPCE
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple